微RNA预后标志物用于免疫检查点抑制剂在尿道癌的成功
Panagiotis J Vlachostergios1,2,3, Konstatinos Evmorfopoulos3, Konstantinos Marsitopoulos3
1Department of Medical Oncology, IASO Thessalias General Hospital, Larissa, Greece.
Immunotherapy
|March 10, 2026
概括
微RNAs (miRNAs) 作为预测尿道癌中免疫检查点抑制剂 (ICI) 反应的生物标志物具有前景. 本综述综合了关于膀,脏和前列腺癌的miRNA预后标记物的证据.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了泌尿癌治疗.
- 患者对ICI的反应是异质的,需要预后生物标志物.
- 微RNAs (miRNAs) 是参与瘤免疫和进展的基因表达的关键调节者.
研究的目的:
- 审查和综合miRNA预后标志物的证据,以预测尿道瘤中ICI的成功.
- 探索这些miRNA标记物的生物功能,临床效用和治疗影响.
- 为提供癌症类型分层的概述,将miRNA机制,生物标志物和免疫治疗联系起来.
主要方法:
- 对调查miRNAs作为尿道癌症中ICI治疗的预后标记物的研究进行系统性文献综述.
- 分析miRNA签名,它们对免疫检查点的作用机制及其预测价值.
- 综合数据按癌症类型分层 (膀,细胞癌,前列腺癌).
主要成果:
- 在泌尿癌中确定了与ICI反应相关的特定miRNA签名.
- 突出了miRNAs在调节免疫检查点路径中的作用.
- 讨论了循环miRNAs作为非侵入性生物标记物的潜力.
结论:
- 在尿道癌症中,miRNAs作为ICI治疗的预后生物标志物具有显著的潜力.
- 微RNA分析可以增强个性化免疫疗法策略.
- 需要进一步的研究来验证和将这些发现转化为临床实践.
相关概念视频
MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...


